Raymond James Reiterates Strong Buy Rating on Tyra Biosciences (TYRA) Oct 6, 2026 05:16AM
William Blair Adjusts October Analyst Conviction List Names Oct 1, 2026 07:11AM
Raymond James Adjusts Analyst Current Favorites List Sep 23, 2026 06:31AM
Tyra Biosciences (TYRA) PT Lowered to $29 at H.C. Wainwright Sep 22, 2026 07:37AM
Cantor Fitzgerald Reiterates Overweight Rating on Tyra Biosciences (TYRA) Sep 14, 2026 09:53AM
View Older Stories

Sep 14, 2026 06:04AM Tyra Biosciences (TYRA) files mixed shelf
Sep 10, 2026 09:26AM Cantor Fitzgerald Reiterates Overweight Rating on Tyra Biosciences (TYRA)
Sep 9, 2026 08:33AM Tyra Biosciences reports Phase 2 data for oral bladder cancer drug
Sep 8, 2026 09:22AM Piper Sandler Reiterates Overweight Rating on Tyra Biosciences (TYRA) Ahead of Dabo IR NMIBC Readout
Sep 8, 2026 07:54AM H.C. Wainwright Reiterates Buy Rating on Tyra Biosciences (TYRA)
Aug 4, 2026 05:46PM Tyra Biosciences, Inc. (TYRA) Misses Q2 EPS by 4c
Jul 1, 2026 06:19AM William Blair Adjusts Monthly Analyst Conviction List for July 2026
Jun 17, 2026 07:08AM Jones Trading Starts Tyra Biosciences (TYRA) at Buy
Jun 17, 2026 06:12AM Oppenheimer Assumes Tyra Biosciences (TYRA) at Outperform
Jun 10, 2026 05:11AM Tyra Biosciences (TYRA) PT Raised to $42 at BofA Securities
Jun 4, 2026 04:54PM Raymond James Reiterates Strong Buy Rating on Tyra Biosciences (TYRA)
May 19, 2026 05:42AM Wolfe Research Starts Tyra Biosciences (TYRA) at Peerperform
Apr 17, 2026 07:52AM Tyra Biosciences (TYRA) Reiterated at Overweight by Cantor Fitzgerald
Apr 14, 2026 04:11PM Guggenheim Starts Tyra Biosciences (TYRA) at Buy
Apr 6, 2026 05:36AM Canaccord Starts Tyra Biosciences (TYRA) at Buy
Mar 26, 2026 09:29AM Piper Sandler on Tyra Biosciences (TYRA): 'We're incrementally positive on dabogratinib's commercial opportunity'
Mar 3, 2026 07:38AM H.C. Wainwright Reiterates Buy Rating on Tyra Biosciences (TYRA)
Mar 3, 2026 07:25AM H.C. Wainwright Reiterates Buy Rating on Tyra Biosciences (TYRA)
Mar 2, 2026 08:17PM Tyra Biosciences, Inc. (TYRA) Misses Q4 EPS by 4c
Feb 10, 2026 06:10AM William Blair Starts Tyra Biosciences (TYRA) at Outperform
Jan 28, 2026 04:15PM Tyra Biosciences (TYRA) PT Raised to $55 at Raymond James
Jan 23, 2026 04:13AM Tyra Biosciences (TYRA) PT Raised to $42 at Piper Sandler, Reiterate Top Pick
Dec 22, 2025 07:06AM Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
Dec 16, 2025 06:20AM Tyra Biosciences (TYRA) PT Raised to $37 at Wedbush, Adds to BIL
Dec 4, 2025 06:58AM Goldman Sachs Starts Tyra Biosciences (TYRA) at Early-Stage Biotech
Nov 5, 2025 04:38PM Tyra Biosciences, Inc. (TYRA) Reports In-Line Q3 EPS
Sep 10, 2025 08:19AM Tyra Biosciences (TYRA) PT Raised to $36 at Oppenheimer
Aug 14, 2025 04:07PM Tyra Biosciences, Inc. (TYRA) Tops Q2 EPS by 6c
Jul 1, 2025 06:52AM H.C. Wainwright Reiterates Buy Rating on Tyra Biosciences (TYRA)
May 21, 2025 06:24AM Piper Sandler Assumes Tyra Biosciences (TYRA) at Overweight
May 8, 2025 07:58PM Tyra Biosciences, Inc. (TYRA) Tops Q1 EPS by 1c
Mar 31, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Tyra Biosciences (TYRA)
Feb 18, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Tyra Biosciences (TYRA)
Jan 29, 2025 04:06PM Tyra Biosciences (TYRA) Appoints Adele Gulfo to its Board
Jan 10, 2025 08:06AM Tyra Biosciences (TYRA) Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer
Jan 7, 2025 06:20AM UBS Starts Tyra Biosciences (TYRA) at Buy
Jan 2, 2025 12:51PM Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
Nov 11, 2024 07:24AM Tyra Biosciences (TYRA) PT Lowered to $30 at H.C. Wainwright
Nov 7, 2024 04:22PM Tyra Biosciences, Inc. (TYRA) Misses Q3 EPS by 1c
Oct 28, 2024 10:42AM Piper Sandler Reiterates Overweight Rating on Tyra Biosciences (TYRA)
Oct 28, 2024 07:00AM Tyra Biosciences (TYRA) Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia
Oct 28, 2024 06:39AM Tyra Biosciences (TYRA) PT Raised to $32 at H.C. Wainwright
Oct 25, 2024 07:12AM TD Cowen Reiterates Buy Rating on Tyra Biosciences (TYRA)
Oct 18, 2024 06:11AM BofA Securities Upgrades Tyra Biosciences (TYRA) to Buy
Oct 11, 2024 09:09AM Piper Sandler Reiterates Overweight Rating on Tyra Biosciences (TYRA)
Oct 11, 2024 08:03AM Tyra Biosciences (TYRA) Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR
Oct 7, 2024 06:33AM Tyra Biosciences (TYRA) PT Raised to $30 at H.C. Wainwright
Oct 3, 2024 06:08AM Piper Sandler Reiterates Overweight Rating on Tyra Biosciences (TYRA)
Sep 19, 2024 07:31AM Tyra Biosciences (TYRA) PT Raised to $33 at Oppenheimer
Sep 10, 2024 04:05PM Tyra Biosciences (TYRA) Appoints Doug Warner as Chief Medical Officer
View Older Stories